BioRestorative Therapies, Inc. (NASDAQ: BRTX)

Sector: Healthcare Industry: Biotechnology CIK: 0001505497
Market Cap 2.33 Mn
P/B 1.05
P/E -0.18
P/S 6.07
ROIC (Qtr) -411.55
Div Yield % 0.00
Rev 1y % (Qtr) -94.95
Total Debt (Qtr) 0.00
Debt/Equity (Qtr) 0.00
Add ratio to table...

About

BioRestorative Therapies, Inc. (BRTX) operates in the biotechnology industry, specifically focusing on the development of therapeutic products and medical therapies using cell and tissue protocols. The company's main business activities are divided into two programs: the Disc/Spine Program and the ThermoStem Program. The Disc/Spine Program is primarily focused on the development of BRTX-100, an autologous hypoxic cultured mesenchymal stem cell product derived from a patient's own bone marrow. This product is formulated with a proprietary biomaterial...

Read more

Investment thesis

Bull case

  • Short-term investments of 3.89M provide solid 1.51x coverage of other current liabilities 2.58M, indicating strong liquidity.
  • Robust tangible asset base of 5.09M provides 4x coverage of working capital 1.27M, indicating strong operational backing.
  • Robust R&D investment of 8.19M at 1.23x of SG&A 6.68M demonstrates strong commitment to innovation and future growth.
  • Short-term investments of 3.89M provide healthy 3.06x coverage of working capital 1.27M, indicating strong liquidity.
  • Strong R&D investment of 8.19M at 167.78x of capex 48834 shows balanced investment in innovation and infrastructure.

Bear case

  • Operating cash flow of (10.72M) barely covers its investment activities of 8.03M, with a coverage ratio of -1.34, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Investment activities of 8.03M provide weak support for R&D spending of 8.19M, which is 0.98x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Short-term investments of 3.89M significantly exceed cash reserves of 602444, which is 6.45x, indicating potentially excessive yield-seeking behavior at the expense of liquidity.
  • The company's operating cash flow of (10.72M) shows concerning coverage of stock compensation expenses of 3.05M, with a -3.51 ratio indicating potential earnings quality issues.
  • Free cash flow of (10.77M) provides weak coverage of capital expenditures of 48834, with a -220.55 ratio suggesting additional external financing needs for growth initiatives.

Peer comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,204.25 Bn -1,306.67 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 486.51 Bn 7,097.20 97.84 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 122.05 Bn 30.87 10.17 1.85 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 83.00 Bn 18.42 5.79 2.71 Bn
5 ARGX Argenx Se 50.78 Bn 33.71 26,480.10 -
6 ALNY Alnylam Pharmaceuticals, Inc. 43.66 Bn 139.17 11.76 2.97 Bn
7 BNTC Benitec Biopharma Inc. 43.61 Bn -941.82 0.00 0.00 Bn
8 INSM INSMED Inc 28.88 Bn -24.40 64.61 0.74 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 0.14 11.06
EV to Cash from Ops. EV/CFO -0.07 26.32
EV to Debt EV to Debt 0.00 762.61
EV to EBIT EV/EBIT -0.06 -13.49
EV to EBITDA EV/EBITDA -0.05 8.61
EV to Free Cash Flow [EV/FCF] EV/FCF -0.07 25.66
EV to Market Cap EV to Market Cap 0.33 203.37
EV to Revenue EV/Rev 2.01 156.31
Price to Book Value [P/B] P/B 1.05 20.59
Price to Earnings [P/E] P/E -0.18 -0.88
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 -12.64
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.17
Dividend per Basic Share Div per Share (Qtr) 0.00 0.01
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.14
Interest Coverage Int. cover (Qtr) 0.00 956.66
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) 70.18 7.87
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) -59.55 753.48
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -31.34 -57.63
EBITDA Growth (1y) % EBITDA 1y % (Qtr) -21.00 8.83
EBIT Growth (1y) % EBIT 1y % (Qtr) -31.34 -67.21
EBT Growth (1y) % EBT 1y % (Qtr) -31.34 -23.74
EPS Growth (1y) % EPS 1y % (Qtr) -2.80 -7.02
FCF Growth (1y) % FCF 1y % (Qtr) -41.08 -40.48
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 1.59 264.51
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.07 0.14
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.00
Cash Ratio Cash Ratio (Qtr) 0.18 3.92
Current Ratio Curr Ratio (Qtr) 1.37 7.33
Debt to Equity Ratio Debt/Equity (Qtr) 0.00 0.48
Interest Cover Ratio Int Coverage (Qtr) 0.00 956.66
Times Interest Earned Times Interest Earned (Qtr) 0.00 956.66
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) -3,240.30 -17,888.70
EBIT Margin % EBIT Margin % (Qtr) -3,304.77 -18,246.34
EBT Margin % EBT Margin % (Qtr) -3,304.77 -19,108.08
Gross Margin % Gross Margin % (Qtr) 93.30 -10.30
Net Profit Margin % Net Margin % (Qtr) -3,304.80 -19,056.96